![Debora Barton](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Debora Barton
Direktor/Vorstandsmitglied bei
American Cancer Society, Inc.
Vermögen: 54 889 $ am 31.08.2026
Profil
Debora Barton is currently the Director at American Cancer Society, Inc. since 2018.
Formerly, Dr. Barton was an Independent Non-Executive Director at Arovella Therapeutics Ltd. from 2021 to 2026, Senior VP, Head-Clinical & Safety at Iovance Biotherapeutics, Inc. from 2018 to 2019, Chief Medical Officer at CTx Operations, Inc. from 2019 to 2022, Chief Medical Officer at Carisma Therapeutics, Inc. from 2019 to 2022, and Chief Medical Officer at TScan Therapeutics, Inc. from 2022 to 2024.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 04.05.2026 | 1.276.490 ( 0,11 % ) | 54 889 $ | 31.08.2026 |
Aktive Positionen von Debora Barton
| Unternehmen | Position | Beginn |
|---|---|---|
American Cancer Society, Inc.
 American Cancer Society, Inc. Miscellaneous Commercial ServicesCommercial Services Operates voluntary health organization for cancer research | Direktor/Vorstandsmitglied | 01.05.2018 |
Ehemalige bekannte Positionen von Debora Barton
| Unternehmen | Position | Ende |
|---|---|---|
| AROVELLA THERAPEUTICS LIMITED | Direktor/Vorstandsmitglied | 04.05.2026 |
| TSCAN THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 08.04.2024 |
CTx Operations, Inc.
 CTx Operations, Inc. BiotechnologyHealth Technology Develops macrophage-based immunotherapeutic for treatment of cancer | Technik-/Wissenschafts-/F&E-Leiter | 01.06.2022 |
| CARISMA THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.06.2022 |
| IOVANCE BIOTHERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.11.2019 |
Ausbildung von Debora Barton
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
63
Beziehungen ersten Grades
7
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
Arovella Therapeutics Ltd.
 Arovella Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals and distributes medical devices and consumables | Health Technology |
American Cancer Society, Inc.
American Cancer Society, Inc. Miscellaneous Commercial ServicesCommercial Services Operates voluntary health organization for cancer research | Commercial Services |
Pontifícia Universidade Católica de São Paulo
 Pontifícia Universidade Católica de São Paulo Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Iovance Biotherapeutics, Inc.
 Iovance Biotherapeutics, Inc. BiotechnologyHealth Technology Develops biotechnological products for the treatment of cancer | Health Technology |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology Develops macrophage-based immunotherapeutic for treatment of cancer | Health Technology |
TScan Therapeutics, Inc.
 TScan Therapeutics, Inc. BiotechnologyHealth Technology Develops T-cell therapies for cancer patients | Health Technology |
Carisma Therapeutics, Inc.
 Carisma Therapeutics, Inc. BiotechnologyHealth Technology Develops novel chimeric antigen receptor macrophage and CAR-monocyte technology treatment of non-muscle invasive bladder cancer | Health Technology |
